Lifecore Biomedical, Inc. (LFCR)
USD 6.17
(6.01%)
USD 6.17
(6.01%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 128.26 Million USD | 24.2% |
| 2023 | 103.26 Million USD | -44.42% |
| 2022 | 185.78 Million USD | -65.86% |
| 2021 | 544.16 Million USD | -7.83% |
| 2020 | 590.36 Million USD | 5.88% |
| 2019 | 557.55 Million USD | 6.36% |
| 2018 | 524.22 Million USD | -1.51% |
| 2017 | 532.25 Million USD | -1.63% |
| 2016 | 541.09 Million USD | 0.34% |
| 2015 | 539.25 Million USD | 13.1% |
| 2014 | 476.81 Million USD | 7.95% |
| 2013 | 441.7 Million USD | 39.1% |
| 2012 | 317.55 Million USD | 14.75% |
| 2011 | 276.72 Million USD | 16.16% |
| 2010 | 238.22 Million USD | 0.97% |
| 2009 | 235.93 Million USD | -1.09% |
| 2008 | 238.52 Million USD | 13.32% |
| 2007 | 210.49 Million USD | -9.25% |
| 2006 | 231.95 Million USD | 13.02% |
| 2005 | 205.23 Million USD | 6.84% |
| 2004 | 192.09 Million USD | 0.0% |
| 2003 | - USD | -100.0% |
| 2002 | 183.15 Million USD | -4.05% |
| 2001 | 190.88 Million USD | -8.91% |
| 2000 | 209.55 Million USD | 491.95% |
| 1999 | 35.4 Million USD | 5.67% |
| 1998 | 33.5 Million USD | 252.63% |
| 1997 | 9.5 Million USD | 280.0% |
| 1996 | 2.5 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 30.15 Million USD | 22.95% |
| 2024 Q1 | 24.52 Million USD | -22.27% |
| 2024 Q3 | 35.7 Million USD | 18.42% |
| 2024 FY | 128.26 Million USD | 24.2% |
| 2024 Q4 | 37.88 Million USD | 6.11% |
| 2023 Q1 | 43.35 Million USD | -8.97% |
| 2023 Q2 | 38.8 Million USD | -10.5% |
| 2023 Q4 | 31.54 Million USD | 14.3% |
| 2023 FY | 103.26 Million USD | -44.42% |
| 2023 Q3 | 27.6 Million USD | -28.87% |
| 2022 Q3 | 53.07 Million USD | -59.01% |
| 2022 Q1 | 128.78 Million USD | -7.9% |
| 2022 Q2 | 129.49 Million USD | 0.55% |
| 2022 Q4 | 47.62 Million USD | -10.26% |
| 2022 FY | 185.78 Million USD | -65.86% |
| 2021 Q4 | 139.83 Million USD | 1.49% |
| 2021 FY | 544.16 Million USD | -7.83% |
| 2021 Q3 | 137.78 Million USD | 5.25% |
| 2021 Q1 | 135.64 Million USD | -13.12% |
| 2021 Q2 | 130.9 Million USD | -3.49% |
| 2020 Q1 | 138.71 Million USD | -9.21% |
| 2020 FY | 590.36 Million USD | 5.88% |
| 2020 Q2 | 142.59 Million USD | 2.8% |
| 2020 Q3 | 152.92 Million USD | 7.25% |
| 2020 Q4 | 156.13 Million USD | 2.09% |
| 2019 Q3 | 155.68 Million USD | 24.64% |
| 2019 FY | 557.55 Million USD | 6.36% |
| 2019 Q4 | 152.78 Million USD | -1.87% |
| 2019 Q1 | 124.66 Million USD | -11.63% |
| 2019 Q2 | 124.91 Million USD | 0.2% |
| 2018 Q4 | 141.07 Million USD | -5.52% |
| 2018 Q3 | 149.32 Million USD | 9.43% |
| 2018 Q2 | 136.45 Million USD | 10.62% |
| 2018 Q1 | 123.35 Million USD | -3.2% |
| 2018 FY | 524.22 Million USD | -1.51% |
| 2017 Q1 | 132.39 Million USD | -2.16% |
| 2017 FY | 532.25 Million USD | -1.63% |
| 2017 Q4 | 127.43 Million USD | -6.69% |
| 2017 Q3 | 136.56 Million USD | 0.52% |
| 2017 Q2 | 135.86 Million USD | 2.62% |
| 2016 FY | 541.09 Million USD | 0.34% |
| 2016 Q3 | 129.99 Million USD | -7.44% |
| 2016 Q4 | 135.31 Million USD | 4.09% |
| 2016 Q1 | 135.35 Million USD | 0.67% |
| 2016 Q2 | 140.44 Million USD | 3.76% |
| 2015 Q3 | 138.53 Million USD | 4.42% |
| 2015 Q4 | 134.44 Million USD | -2.95% |
| 2015 FY | 539.25 Million USD | 13.1% |
| 2015 Q2 | 132.66 Million USD | -0.71% |
| 2015 Q1 | 133.61 Million USD | 10.49% |
| 2014 Q4 | 120.92 Million USD | -4.31% |
| 2014 Q2 | 120.02 Million USD | 9.63% |
| 2014 Q1 | 109.47 Million USD | 2.21% |
| 2014 FY | 476.81 Million USD | 7.95% |
| 2014 Q3 | 126.37 Million USD | 5.29% |
| 2013 Q3 | 117.86 Million USD | 2.8% |
| 2013 Q1 | 102.07 Million USD | 23.55% |
| 2013 Q4 | 107.11 Million USD | -9.12% |
| 2013 Q2 | 114.65 Million USD | 12.32% |
| 2013 FY | 441.7 Million USD | 39.1% |
| 2012 Q2 | 81.57 Million USD | 11.28% |
| 2012 Q4 | 82.61 Million USD | 3.19% |
| 2012 FY | 317.55 Million USD | 14.75% |
| 2012 Q1 | 73.3 Million USD | 7.64% |
| 2012 Q3 | 80.06 Million USD | -1.85% |
| 2011 FY | 276.72 Million USD | 16.16% |
| 2011 Q2 | 70.16 Million USD | 8.03% |
| 2011 Q3 | 73.5 Million USD | 4.76% |
| 2011 Q4 | 68.09 Million USD | -7.36% |
| 2011 Q1 | 64.95 Million USD | 11.57% |
| 2010 FY | 238.22 Million USD | 0.97% |
| 2010 Q3 | 58.13 Million USD | -4.6% |
| 2010 Q1 | 60.94 Million USD | 16.67% |
| 2010 Q2 | 60.93 Million USD | -0.02% |
| 2010 Q4 | 58.21 Million USD | 0.14% |
| 2009 Q2 | 58.03 Million USD | -19.11% |
| 2009 FY | 235.93 Million USD | -1.09% |
| 2009 Q4 | 52.23 Million USD | -3.11% |
| 2009 Q1 | 71.75 Million USD | 25.22% |
| 2009 Q3 | 53.91 Million USD | -7.11% |
| 2008 Q2 | 58.96 Million USD | -5.9% |
| 2008 FY | 238.52 Million USD | 13.32% |
| 2008 Q4 | 57.3 Million USD | -3.87% |
| 2008 Q3 | 59.6 Million USD | 1.1% |
| 2008 Q1 | 62.65 Million USD | 22.38% |
| 2007 FY | 210.49 Million USD | -9.25% |
| 2007 Q4 | 51.2 Million USD | -3.31% |
| 2007 Q3 | 52.95 Million USD | -4.06% |
| 2007 Q2 | 55.19 Million USD | 7.91% |
| 2007 Q1 | 51.14 Million USD | -28.25% |
| 2006 Q1 | 49.7 Million USD | -11.51% |
| 2006 FY | 231.95 Million USD | 13.02% |
| 2006 Q2 | 53.71 Million USD | 8.06% |
| 2006 Q3 | 57.24 Million USD | 6.59% |
| 2006 Q4 | 71.28 Million USD | 24.52% |
| 2005 Q3 | 51.53 Million USD | 1.7% |
| 2005 FY | 205.23 Million USD | 6.84% |
| 2005 Q4 | 56.17 Million USD | 9.01% |
| 2005 Q2 | 50.67 Million USD | 8.15% |
| 2005 Q1 | 46.85 Million USD | -19.82% |
| 2004 Q1 | 41.8 Million USD | -26.46% |
| 2004 Q3 | 48.58 Million USD | 12.3% |
| 2004 Q4 | 58.43 Million USD | 20.27% |
| 2004 FY | 192.09 Million USD | 0.0% |
| 2004 Q2 | 43.26 Million USD | 3.5% |
| 2003 Q2 | 41.22 Million USD | -7.3% |
| 2003 Q3 | 41.12 Million USD | -0.23% |
| 2003 FY | - USD | -100.0% |
| 2003 Q4 | 56.84 Million USD | 38.22% |
| 2003 Q1 | 44.46 Million USD | -22.15% |
| 2002 Q4 | 57.12 Million USD | 41.58% |
| 2002 Q1 | 50.21 Million USD | -19.35% |
| 2002 Q2 | 30.3 Million USD | -39.64% |
| 2002 Q3 | 40.34 Million USD | 33.12% |
| 2002 FY | 183.15 Million USD | -4.05% |
| 2001 Q4 | 62.26 Million USD | 29.45% |
| 2001 Q3 | 48.09 Million USD | -10.24% |
| 2001 Q2 | 53.58 Million USD | -12.74% |
| 2001 Q1 | 61.4 Million USD | 1.04% |
| 2001 FY | 190.88 Million USD | -8.91% |
| 2000 FY | 209.55 Million USD | 491.95% |
| 2000 Q2 | 5.5 Million USD | 0.0% |
| 2000 Q4 | 60.77 Million USD | 79.8% |
| 2000 Q3 | 33.8 Million USD | 514.55% |
| 2000 Q1 | 5.5 Million USD | -71.2% |
| 1999 Q1 | 5.3 Million USD | -70.39% |
| 1999 Q2 | 5.2 Million USD | -1.89% |
| 1999 Q3 | 5.3 Million USD | 1.92% |
| 1999 Q4 | 19.1 Million USD | 260.38% |
| 1999 FY | 35.4 Million USD | 5.67% |
| 1998 Q2 | 3.8 Million USD | -11.63% |
| 1998 Q3 | 5.1 Million USD | 34.21% |
| 1998 Q4 | 17.9 Million USD | 250.98% |
| 1998 FY | 33.5 Million USD | 252.63% |
| 1998 Q1 | 4.3 Million USD | 330.0% |
| 1997 FY | 9.5 Million USD | 280.0% |
| 1997 Q2 | 300 Thousand USD | -40.0% |
| 1997 Q3 | 400 Thousand USD | 33.33% |
| 1997 Q4 | 1 Million USD | 150.0% |
| 1997 Q1 | 500 Thousand USD | -61.54% |
| 1996 Q3 | 400 Thousand USD | 0.0% |
| 1996 FY | 2.5 Million USD | 0.0% |
| 1996 Q4 | 1.3 Million USD | 225.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 77.37% |
| Embecta Corp. | 1.12 Billion USD | 88.556% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 73.653% |
| Dynavax Technologies Corporation | 232.28 Million USD | 44.783% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -10.252% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 80.998% |
| PainReform Ltd. | - USD | -Infinity% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -153.565% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -432.363% |
| SCYNEXIS, Inc. | 140.14 Million USD | 8.477% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -6550.827% |
| Cosmos Health Inc. | 53.37 Million USD | -140.293% |
| Journey Medical Corporation | 79.18 Million USD | -61.985% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -432.363% |
| Safety Shot Inc | 202.67 Thousand USD | -63185.637% |
| Alpha Teknova, Inc. | 36.68 Million USD | -249.637% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 72.38% |
| Bright Green Corporation | 401.49 Thousand USD | -31846.171% |
| Procaps Group, S.A. | 409.92 Million USD | 68.711% |
| Theratechnologies Inc. | 81.76 Million USD | -56.867% |
| Harrow Health, Inc. | 130.19 Million USD | 1.484% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -907.154% |
| Biofrontera Inc. | 34.07 Million USD | -276.452% |
| DURECT Corporation | 8.54 Million USD | -1400.48% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 78.888% |
| Cronos Group Inc. | 88.84 Million USD | -44.372% |
| OptiNose, Inc. | 70.98 Million USD | -80.682% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 71.03% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -1869.255% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 70.388% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -947.153% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -224.28% |
| Radius Health, Inc. | 2.88 Billion USD | 95.55% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -296.986% |
| ProPhase Labs, Inc. | 44.38 Million USD | -188.98% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 87.397% |
| Procaps Group S.A. | 409.92 Million USD | 68.711% |
| Alvotech | 91.43 Million USD | -40.277% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -9751.075% |
| Viatris Inc. | 15.42 Billion USD | 99.169% |
| Rockwell Medical, Inc. | 83.61 Million USD | -53.4% |
| Aytu BioPharma, Inc. | 81 Million USD | -58.343% |
| SIGA Technologies, Inc. | 139.91 Million USD | 8.331% |
| Tilray Brands, Inc. | 788.94 Million USD | 83.743% |
| Shineco, Inc. | 9.8 Million USD | -1208.538% |
| PetIQ, Inc. | 1.1 Billion USD | 88.361% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 12 Thousand USD | -1068741.667% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 93.203% |
| Alimera Sciences, Inc. | 80.75 Million USD | -58.829% |
| Silver Spike Investment Corp. | 11.72 Million USD | -994.178% |
| Assertio Holdings, Inc. | 152.06 Million USD | 15.656% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -2102.893% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -636.413% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -11815.682% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -358.681% |
| Hempacco Co., Inc. | 4.04 Million USD | -3070.354% |
| Talphera, Inc. | 651 Thousand USD | -19602.151% |
| Alvotech | 91.43 Million USD | -40.277% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | 59.489% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 90.107% |
| Currenc Group, Inc. | 53.25 Million USD | -140.841% |
| Kamada Ltd. | 144.75 Million USD | 11.397% |
| Indivior PLC | 1.09 Billion USD | 88.265% |
| Evoke Pharma, Inc. | 5.18 Million USD | -2375.78% |
| Flora Growth Corp. | 76.07 Million USD | -68.607% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -11815.682% |
| Evolus, Inc. | 202.08 Million USD | 36.531% |
| HUTCHMED (China) Limited | 837.99 Million USD | 84.694% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 80.096% |
| Akanda Corp. | 2.16 Million USD | -5837.866% |